Market Overview

First Solar, Intermolecular Extend, Expand Licensing Deal

Related IMI
Morgan Stanley Reacts To Intermolecular CEO Transition
5 Strong Buy Healthcare Funds to Bet on - Mutual Fund Commentary
Related FSLR
Janney Desk Comments: Expecting Fist Solar To Benefit From 8Point3 Energy Partners Report Tonight; FSLR Could Steal Attention Away From SUNE
Solar ETF And Stocks Getting Hammered: Here's Why
SunEdison Completes 1.2MW of Solar Project in Minnesota (Zacks)

Intermolecular, Inc. (Nasdaq: IMI) and First Solar, Inc. (Nasdaq: FSLR) today announced they have entered into a two-year collaboration and licensing agreement focused on further increases to the conversion efficiency of First Solar's cadmium telluride (CdTe) solar cell technology. Under the new collaborative development program, First Solar and Intermolecular researchers will work together to develop disruptive new approaches to increasing the performance of CdTe solar cell technology using Intermolecular's proprietary High Productivity Combinatorial (HPC™) platform. The program targets substantial gains in First Solar's module conversion efficiency beyond its previously announced roadmap.

Posted-In: News


Related Articles (FSLR + IMI)

View Comments and Join the Discussion!

Get Benzinga's Newsletters